Komori
Alfresa Holdings (2784) · FactFirst stated

FY2022-Q3 Prescription Pharmaceuticals and Other Products Wholesale Business: Lower Revenue and Profit

First written in FY2022-Q3. . Latest entry: FY2022-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Lower revenue and earnings in the wholesale business for prescription drugs and other pharmaceuticalsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2022-Q3First statedAnnual report

    「当セグメントの当第３四半期連結累計期間の業績は、新型コロナウイルス感染拡大および独占禁止法違反による医療機関の入札指名停止の影響に加えて、2021年４月に薬価の中間年改定が実施されたなか、販売価格の管理を強化し売上総利益率を維持した一方で、減価償却費等の経費が増加したこと等の影響により、売上高1兆7,379億25百万円(前年同期は1兆7,519億33百万円)、営業利益158億4百万円(同175億95百万円)となりました。」

    医療用医薬品等卸売事業は、前年同期比で減収減益となった。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.